SF3B1 and myelodysplastic syndrome: Based on the clinical implications in terms of risk stratification and therapeutic decision making, the 2016 WHO classification has included SF3B1-mutant MDS as a diagnostic criterion for MDS-RS with a positive predictive value of 98% [41].